Jw Life Science Corp (234080) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.023x

Based on the latest financial reports, Jw Life Science Corp (234080) has a cash flow conversion efficiency ratio of 0.023x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩5.08 Billion ≈ $3.44 Million USD) by net assets (₩220.58 Billion ≈ $149.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 234080 equity to assets ratio to measure how much of total assets are equity-financed.

Jw Life Science Corp - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Jw Life Science Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 234080 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Jw Life Science Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Jw Life Science Corp ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Kulmbacher Brauerei Aktien-Gesellschaft MU:KUL	0.001x
Gold Resource Corporation NYSE MKT:GORO	-0.013x
San Juan Basin Royalty Trust NYSE:SJT	-0.114x
eGalax_eMPIA Technology TWO:3556	0.066x
Distribuidora de Gas Cuyana SA BA:DGCU2	0.138x
DAM CAPITAL ADVISORS LTD NSE:DAMCAPITAL	0.011x
Nava Nakorn Public Company Limited BK:NNCL	0.023x
Willbes KO:008600	0.151x

Annual Cash Flow Conversion Efficiency for Jw Life Science Corp (2015–2025)

The table below shows the annual cash flow conversion efficiency of Jw Life Science Corp from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see 234080 stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩220.58 Billion ≈ $149.48 Million	₩40.54 Billion ≈ $27.47 Million	0.184x	-27.33%
2024-12-31	₩200.44 Billion ≈ $135.84 Million	₩50.69 Billion ≈ $34.35 Million	0.253x	+7.28%
2023-12-31	₩159.39 Billion ≈ $108.02 Million	₩37.57 Billion ≈ $25.46 Million	0.236x	+134.14%
2022-12-31	₩140.33 Billion ≈ $95.10 Million	₩14.13 Billion ≈ $9.57 Million	0.101x	-56.11%
2021-12-31	₩131.49 Billion ≈ $89.11 Million	₩30.17 Billion ≈ $20.44 Million	0.229x	-35.20%
2020-12-31	₩132.06 Billion ≈ $89.50 Million	₩46.75 Billion ≈ $31.68 Million	0.354x	+78.82%
2019-12-31	₩122.62 Billion ≈ $83.09 Million	₩24.28 Billion ≈ $16.45 Million	0.198x	-40.13%
2018-12-31	₩109.26 Billion ≈ $74.04 Million	₩36.13 Billion ≈ $24.48 Million	0.331x	+53.12%
2017-12-31	₩102.10 Billion ≈ $69.19 Million	₩22.05 Billion ≈ $14.94 Million	0.216x	+21.27%
2016-12-31	₩90.30 Billion ≈ $61.20 Million	₩16.08 Billion ≈ $10.90 Million	0.178x	-43.04%
2015-12-31	₩82.83 Billion ≈ $56.13 Million	₩25.90 Billion ≈ $17.55 Million	0.313x	--

About Jw Life Science Corp

KO:234080 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$116.90 Million

₩172.50 Billion KRW

Market Cap Rank

#18530 Global

#803 in Korea

Share Price

₩11140.00

Change (1 day)

+1.92%

52-Week Range

₩10720.00 - ₩15500.00

All Time High

₩26817.34